15 Results

People

  1. Drullinsky
    Drullinsky
  2. Matasar
    Matasar
  3. Schoder
    Schoder
  4. Zelenetz
    Zelenetz
  5. Kumar
    Kumar
  6. Hamlin
    Hamlin
  7. Moskowitz
    Moskowitz
  8. Younes
    Younes
  9. Batlevi
    Batlevi
  10. Hamilton
    Hamilton

Groups

  1. Breast Medicine Service (15)
  2. Center for Hematologic Malignancies (15)
  3. Department of Medicine (15)
  4. Hematologic Malignancies, Division of (15)
  5. Lymphoma (15)
  6. Molecular Imaging and Therapy Service (15)
  7. Radiology, Department of (15)
  8. Solid Tumor Oncology Division (15)
  9. Survivorship Research (15)
  10. Executive Committee, Center for Hematologic Malignancies (12)
  1. "Molecular Imaging and Therapy Service"
  2. "Breast Medicine Service"
  3. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (4)
Groups
  1. Breast Medicine Service (15)
  2. Center for Hematologic Malignancies (15)
  3. Department of Medicine (15)
  4. Hematologic Malignancies, Division of (15)
  5. Lymphoma (15)
  6. Molecular Imaging and Therapy Service (15)

More Groups

People
  1. Andrew Zelenetz (15)
  2. David Straus (15)
  3. Heiko Schoder (15)
  4. Matthew Matasar (15)
  5. Pamela Drullinsky (15)
  6. Anita Kumar (14)

More People

Years
  1. 2022 (2)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (3)
  6. 2017 (5)

More Years

Publications
  1. Blood (8)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. Clinical Cancer Research (1)
Publishers
  1. American Society of Hematology (8)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (3)
  4. American Association for Cancer Research (1)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study
    Meeting Abstract

    Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save